平安医药及医疗器械创新ETF(516820)财务指标
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 本期已实现收益 |
-50,758,460.29 |
-213,168,941.26 |
-114,165,710.23 |
-314,480,935.69 |
| 本期利润 |
81,706,502.52 |
-221,576,769.56 |
-326,551,098.32 |
-271,166,692.60 |
| 加权平均基金份额本期利润 |
0.02 |
-0.06 |
-0.10 |
-0.10 |
| 本期加权平均净值利润率(%) |
5.01 |
-17.49 |
-28.28 |
-23.41 |
| 本期基金份额净值增长率(%) |
4.50 |
-18.22 |
-24.32 |
-22.67 |
| 期末可供分配利润 |
-2,767,438,591.50 |
-3,292,851,239.52 |
-2,605,729,447.47 |
-1,764,756,908.63 |
| 期末可供分配基金份额利润 |
-0.65 |
-0.66 |
-0.69 |
-0.59 |
| 期末基金资产净值 |
1,491,976,657.50 |
1,660,564,009.48 |
1,171,685,801.53 |
1,225,658,340.37 |
| 期末基金份额净值 |
0.35 |
0.34 |
0.31 |
0.41 |
| 基金份额累计净值增长率(%) |
-64.97 |
-66.48 |
-68.98 |
-59.01 |
微信公众号
证券之星APP
基本资料
